1. World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19, 11 March 2020. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the- media-briefing-on-covid-19 11-march-2020# (accessed on 9 May 2022).
2. Pormohammad, A.; Ghorbani, S.; Khatami, A.; Razizadeh, M.H.; Alborzi, E.; Zarei, M.; Idrovo, J.P.; Turner, R.J. Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev. Med. Virol. 2021, 31, e2179. [CrossRef] [PubMed]
3. Madewell, Z.J.; Yang, Y.; Longini, I.M., Jr.; Halloran, M.E.; Dean, N.E. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: An updated systematic review and meta-analysis. JAMA Netw. Open 2022, 5, e229317. [CrossRef] [PubMed]
4. Sanjuán, R.; Domingo-Calap, P. Mechanisms of viral mutation. Cell Mol. Life Sci. 2016, 73, 4433–4448. [CrossRef] [PubMed]
5. Bakhshandeh, B.; Jahanafrooz, Z.; Abbasi, A.; Goli, M.B.; Sadeghi, M.; Mottaqi, M.S.; Zamani, M. Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus. Microb. Pathog. 2021, 154, 104831. [CrossRef] [PubMed]
6. World Health Organization. Coronavirus Disease (COVID-19): How Is It Transmitted? Available online: https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19-how-is- it-transmitted (accessed on 10 May 2022).
7. Goel, R.R.; Painter, M.M.; Apostolidis, S.A.; Mathew, D.; Meng, W.; Rosenfeld, A.M.; Lundgreen, K.A.; Reynaldi, A.; Khoury, D.S.; Pattekar, A.; et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 2021, 374, abm0829. [CrossRef] [PubMed]
8. Tartof, S.Y.; Slezak, J.M.; Fischer, H.; Hong, V.; Ackerson, B.K.; Ranasinghe, O.N.; Frankland, T.B.; Ogun, O.A.; Zamparo, J.M.; Gray, S.; et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. Lancet 2021, 398, 1407–1416. [CrossRef]
9. Chemaitelly, H.; Tang, P.; Hasan, M.R.; AlMukdad, S.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Coyle, P.; Ayoub, H.H.; Al Kanaani, Z.; et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N. Engl. J. Med. 2021, 385, e83. [CrossRef] [PubMed]
10. Levin, E.G.; Lustig, Y.; Cohen, C.; Fluss, R.; Indenbaum, V.; Amit, S.; Doolman, R.; Asraf, K.; Mendelson, E.; Ziv, A.; et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N. Engl. J. Med. 2021, 385, e84. [CrossRef]
11. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N. Engl. J. Med. 2021, 385, 1393–1400. [CrossRef]
12. Munro, A.P.S.; Janani, L.; Cornelius, V.; Aley, P.K.; Babbage, G.; Baxter, D.; Bula, M.; Cathie, K.; Chatterjee, K.; Dodd, K.; et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021, 398, 2258–2276. [CrossRef]
13. Moreira, E.D.; Kitchin, N., Jr.; Xu, X.; Dychter, S.S.; Lockhart, S.; Gurtman, A.; Perez, J.L.; Zerbini, C.; Dever, M.E.; Jennings, T.W.; et al. Safety and Efficacy of a Third Dose of BNT162b2 COVID-19 Vaccine. N. Engl. J. Med. 2022, 5, e229317. [CrossRef] [PubMed]
14. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [CrossRef] [PubMed]
15. Chapin-Bardales, J.; Gee, J.; Myers, T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA 2021, 325, 2201–2202. [CrossRef] [PubMed]
16. Urakawa, R.; Isomura, E.T.; Matsunaga, K.; Kubota, K.; Ike, M. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: A cross-sectional study. BMC Infect. Dis. 2022, 22, 179. [CrossRef] [PubMed]
17. Taneja, V. Sex Hormones Determine Immune Response. Front. Immunol. 2018, 9, 1931. [CrossRef] [PubMed]
18. Nikolich-Žugich, J. The Twilight of Immunity: Emerging Concepts in Aging of the Immune System. Nat. Immunol. 2018, 19, 10–19. [CrossRef] [PubMed]
19. COVID-19 Vaccines (Ongoing Topics)—Prime Minister of Japan and His Cabinet. Available online: https://japan.kantei.go.jp/ ongoingtopics/vaccine.html (accessed on 6 May 2022).
20. Centers for Disease Control and Prevention. COVID-19 Vaccine Booster Dose Safety. Available online: https://www.cdc.gov/ vaccines/acip/meetings/downloads/slides-2021-11-19/04-COVID-Shimabukuro-508.pdf (accessed on 6 May 2022).
21. Auster, O.; Finkel, U.; Dagan, N.; Barda, N.; Laufer, A.; Balicer, R.D.; Ben-Shachar, S. Short-term adverse events after the third dose of the BNT162b2 mRNA COVID-19 vaccine in adults 60 Years or older. JAMA Netw. Open 2022, 5, e227657. [CrossRef] [PubMed]
22. Liu, G.; Carter, B.; Gifford, D.K. Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets. Cell Syst. 2021, 12, 102–107.e4. [CrossRef]
23. Notarte, K.I.; Ver, A.T.; Velasco, J.V.; Pastrana, A.; Catahay, J.A.; Salvagno, G.L.; Yap, E.P.H.; Martinez-Sobrido, L.; BTorrelles, J.; Lippi, G.; et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer- BioNTech mRNA vaccination: A systematic review. Crit. Rev. Clin. Lab. Sci. 2022, 28, 1–18. [CrossRef]
24. Notarte, K.I.; Guerrero-Arguero, I.; Velasco, J.V.; Ver, A.T.; Santos de Oliveira, M.H.; Catahay, J.A.; Khan, M.S.R.; Pastrana, A.; Juszczyk, G.; Torrelles, J.B.; et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J. Med. Virol. 2022, 94, 2939–2961. [CrossRef] [PubMed]